Study Showing Co Relation between Microalbuminuria and Hypertension among Type 2 Diabetes Patients

Introduction

Type 2 diabetes mellitus (T2DM) is a prevalent and escalating global health concern, characterized by chronic hyperglycaemia and associated with a spectrum of complications. One of the notable microvascular complications of T2DM is diabetic nephropathy, which can significantly impair renal function and contribute to cardiovascular morbidity. Among the early markers of diabetic nephropathy, microalbuminuria—defined as the presence of a small amount of albumin in the urine—has emerged as a critical indicator of kidney damage and an increased risk for adverse cardiovascular outcomes [1].

Hypertension, a common comorbidity in patients with T2DM, further exacerbates renal damage and accelerates the progression of nephropathy. The interplay between microalbuminuria and hypertension is complex, with each condition potentially influencing the onset and progression of the other. Elevated blood pressure can worsen renal function and promote albuminuria, while the presence of microalbuminuria may reflect underlying vascular dysfunction that contributes to hypertension [2].

Understanding the correlation between microalbuminuria and hypertension in T2DM patients is crucial for early intervention and management strategies. By elucidating the relationship between these two conditions, healthcare providers can better identify patients at higher risk of progressive renal and cardiovascular complications, thus improving patient outcomes through tailored therapeutic approaches [3-5].

Aim and Objectives

This study aims to explorethe correlation between microalbuminuria and hypertension among individuals with Type 2 diabetes, shedding light on their interrelationship and potential implications for clinical practice. Through a comprehensive analysis, we seek to enhance our understanding of how these conditions interact and inform strategies for more effective management and prevention of related complications.

Material and methods

Study Design

This study utilized a cross-sectional design to investigate the correlation between microalbuminuria and hypertension among patients with Type 2 diabetes mellitus (T2DM). The study was conducted at BR Diabetes Care Centre, a specialised Diabetes Care Centre, from Jan 2024 to June 2024. The protocol was approved by the institutional review board, and informed consent was obtained from all participants.

Participants

Inclusion Criteria

• Adults aged 40-70 years.

• Diagnosed with Type 2 diabetes mellitus for at least one year.

• Providing written informed consent to participate in the study.

Exclusion Criteria:

• History of type 1 diabetes mellitus.

• Severe renal impairment (eGFR < 30 mL/min/1.73 m²).

• Pregnancy or lactation.

• Presence of secondary causes of hypertension or microalbuminuria (e.g., primary kidney disease, malignancies).

Sample Size

A total of 200 patients with T2DM were recruited based on convenience sampling. The sample size was calculated to ensure adequate power for detecting significant correlations and associations.

Data Collection

Clinical Assessment

Participants underwent a comprehensive clinical assessment, including demographic data, medical history, and lifestyle factors. The following measurements were collected:

Blood Pressure

Measured using a standard sphygmomanometer after a 5-minute rest in a seated position. Three readings were taken at 1-minute intervals, and the average was used for analysis.

Body Mass Index (BMI)

Calculated as weight in kilograms divided by height in meters squared.

Laboratory Tests:

Microalbuminuria:

Urinary albumin-to-creatinine ratio (UACR) was measured using a spot urine sample. Microalbuminuria was defined as a UACR ≥ 30 mg/g but < 300 mg/g.

Blood Glucose and HbA1c:

Fasting blood glucose levels and HbA1c were measured using standard laboratory techniques.

Hypertension Classification:

Hypertension was classified according to the 2017 American College of Cardiology/American Heart Association (ACC/ AHA) guidelines:

o Normal: Systolic BP < 120 mmHg and Diastolic BP < 80 mmHg.

o Elevated: Systolic BP 120-129 mmHg and Diastolic BP < 80 mmHg.

o Hypertension Stage 1: Systolic BP 130-139 mmHg or Diastolic BP 80-89 mmHg.

o Hypertension Stage 2: Systolic BP ≥ 140 mmHg or Diastolic BP ≥ 90 mmHg.

Statistical Analysis

Descriptive Statistics:

• Demographic and clinical characteristics of the study population were summarized using mean ± standard deviation for continuous variables and frequency (percentage) for categorical variables.

Correlation Analysis:

• Pearson correlation coefficient was used to assess the relationship between microalbuminuria and systolic and diastolic blood pressure.

Comparison of Groups:

• Independent t-tests or Mann-Whitney U tests were used to compare blood pressure levels between patients with and without microalbuminuria.

Regression Analysis:

• Logistic regression analysis was performed to evaluate the association between microalbuminuria and hypertension, adjusting for potential confounders such as age, BMI, and smoking status.

Odds ratios (OR) with 95% confidence intervals (CI) were reported.

Statistical Software:

• All statistical analyses were performed using SPSS version 27.0. A p-value of less than 0.05 was considered statistically significant.

Ethical Considerations

The study was conducted in accordance with the Declaration of Helsinki and ethical guidelines provided by the institutional review board. All participants provided written informed consent prior to their inclusion in the study. By following these procedures, this study aimed to provide a comprehensive analysis of the relationship between microalbuminuria and hypertension in patients with Type 2 diabetes, contributing valuable insights to the understanding and management of these interconnected conditions.

Results

                                               Table 1: Patient Demographics and Baseline Characteristics

                                                 Table 2: Prevalence of Microalbuminuria and Hypertension

Table 3: Distribution of Blood Pressure Categories among Patients with and without Microalbuminuria

Table 4: Correlation between Microalbuminuria and Hypertension

Table 5: Logistic Regression Analysis for the Association between Microalbuminuria and Hypertension

Conclusion

In this cross-sectional study, we explored the correlation between microalbuminuria and hypertension among patients with Type 2 diabetes mellitus (T2DM). Our findings reveal a significant association between the presence of microalbuminuria and elevated blood pressure levels, highlighting a critical link between renal and cardiovascular health in this patient population.

The analysis demonstrated that patients with microalbuminuria were more likely to have higher systolic and diastolic blood pressure compared to those without microalbuminuria. Specifically, the correlation coefficients and logistic regression results suggest that microalbuminuria is positively associated with increased blood pressure and a higher likelihood of hypertension. These findings underscore the role of microalbuminuria as an early marker of vascular dysfunction and potential hypertension in T2DM patients.

The study also identified that age, BMI, and smoking status influence the relationship between microalbuminuria and hypertension. This emphasizes the need for comprehensive management strategies that address both renal and cardiovascular risk factors in patients with T2DM.

Our results have important clinical implications. Routine screening for microalbuminuria in T2DM patients could be a valuable tool for identifying those at higher risk of developing hypertension and subsequent cardiovascular complications. Furthermore, integrating blood pressure management into the care plan for patients with microalbuminuria may help prevent the progression of renal damage and improve overall patient outcomes.

In summary, this study reinforces the significance of monitoring microalbuminuria and blood pressure in the management of Type 2 diabetes mellitus. Future longitudinal studies are warranted to further investigate the causative pathways and to develop targeted interventions aimed at mitigating the adverse effects of microalbuminuria and hypertension in this vulnerable population.

References

1. Epstein, M., & Sowers, J. R. (1992). Diabetes mellitus and hypertension. Hypertension, 19(5), 403-418.
2. Christensen, C. K., & Mogensen, C. E. (1985). The course of incipient diabetic nephropathy: studies of albumin excretion and blood pressure. Diabetic Medicine, 2(2), 97-102.
3. Cordonnier, D., Bayle, F., Benhamou, P. Y., Milongo, R., Zaoui, P., Maynard, C., & Halimi, S. (1993). Future trends of management of renal failure in diabetics. Kidney international. Supplement, 41, S8-13.
4. Adler, A. I., Stratton, I. M., Neil, H. A. W., Yudkin, J. S.,Matthews, D. R., Cull, C. A., ... & Holman, R. R. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Bmj, 321(7258), 412-419.
5. American Diabetes Asociation. (2009). Standards of medical care in diabetes. Diabetes Care. Actualización Médica Periódica, 32(s1).
6. Evans TC, Capell P. Diabetic nephropathy. Clinical Diabetes.2000;18(1).
7. World Health Organization. (1999). International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. Clinical & Experimental Hypertension, 21(5-6), 1009-1060.
8. IDF, D. A. (2021). International diabetes federation. Diabetes Research and Clinical Practice, 102(2).
9. Amos, A. F., McCarty, D. J., & Zimmet, P. (1997). The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic medicine, 14(S5), S7-S85.
10. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
11. Ritz, E., Rychlík, I., Locatelli, F., & Halimi, S. (1999). End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. American journal of kidney diseases, 34(5), 795-808.
12. Ritz, E., & Orth, S. R. (1999). Nephropathy in patients with type 2 diabetes mellitus. New England Journal of Medicine, 341(15), 1127-1133.
13. Parving HH. Diabetic Nephropathy: Prevention and treatment. Kidney Int. 2001;60:2041-2055.
14. Hillege, Hans L., Vaclav Fidler, Gilles FH Diercks, Wiek H. van Gilst, Dick de Zeeuw, Dirk J. van Veldhuisen, Rijk OB Gans, Wilbert MT Janssen, Diederick E. Grobbee, and Paul E. de Jong. "Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population." Circulation 106, no. 14 (2002): 1777-1782.
15. Ruggenenti P, Remuzzi G. Time to abonden microalbuminuria? Kidney Int. 2006;70:1214-1222.